Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 156

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 156
---
-----:|:----|:----|------:|
| Professional services            |     |                          |  282 |     |     |   422 |
| Payroll and related expenses     |     |                          |  234 |     |     |   202 |
| Rent and office maintenance      |     |                          |   22 |     |     |    22 |
| Share-based compensation expense |     |                          |   45 |     |     |   292 |
| Others                           |     |                          |   90 |     |     |   186 |
|                                  |     |                          |  673 |     |     | 1,124 |

NOTE 8 – SUBSEQUENT EVENTS

The Company evaluated subsequent events
through the date these financial statements were available to be issued. The Company concluded that no subsequent events have occurred
that would require recognition or disclosure in the financial statements, except:

| 1. | Increase the number of shares available for issuance under the Company's Global Share Incentive Plan (2021) 
 to 20,000,000.                                                                                              |

| 2. | A grant to Company’s Chief Executive officer 3,800,000 stock options at an exercise price of $0.001                                          
 per share. Of the options granted, options for 50% of the options was fully vested upon grant and the remaining 50% will vest on a quarterly 
 basis over the following years in equal quarterly instalments of 237,500 shares. The options exercisable within eight years from grant       
 date.                                                                                                                                        |

| 3. | A grant to one of Company’s directors 160,000 stock options at an exercise price of $0.40 per share.                                    
 Of the options granted, options for 50% of the options was fully vested upon grant and the remaining 50% will vest on a quarterly basis 
 over two years in equal quarterly instalments of 10,000 shares. The options exercisable within eight years from grant date.             |

<div align='center'>F-47</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SUBSEQUENT EVENTS (Cont.)

| b. | On July 23, 2024, the transactions contemplated under the Stock Exchange Agreement referred to in Note                                          
 1(b) were closed and as a result LipoV